Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | GOT1 | P17174 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440038 | 0.82 | KMT2A (0.69) | KMT2ALMNAPKMMEN1TSHR | |
| SCHEMBL29648045 | 0.82 | KMT2A (0.69) | KMT2ALMNAPKMMEN1TSHR | |
| SCHEMBL1268259 | 0.80 | KMT2A (0.67) | KMT2ALMNAMEN1TSHRPDE10A | |
| SCHEMBL22582748 | 0.80 | LMNA (0.66) | KMT2ALMNAPDE10ACYP2D6HPGD | |
| SCHEMBL31572203 | 0.80 | LMNA (0.66) | KMT2ALMNAPDE10ACYP2D6HPGD | |
| SCHEMBL4015416 | 0.78 | HRH4 (0.63) | KMT2ALMNAAKT2KITGSK3B | |
| SCHEMBL22440005 | 0.78 | LMNA (0.63) | KMT2ALMNAKDM4EALDH1A1MAPT | |
| SCHEMBL30552303 | 0.78 | LMNA (0.63) | KMT2ALMNAMEN1TSHRPDE10A | |
| SCHEMBL2274982 | 0.78 | LMNA (0.63) | KMT2ALMNAMEN1TSHRPDE10A | |
| SCHEMBL1268472 | 0.77 | LMNA (0.55) | KMT2ALMNAPKMMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831042-B1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INT BV (NL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-9321724-B2 | Heteroaryl compounds with A-cyclic bridging unit | INTERVET INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9260441-B2 | Heteroaryl compounds with cyclic bridging unit | INTERVET INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150080365-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2831042-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | Intervet International B.V. (NL) | 2015-02-04 | — | — | EP | disclosed |
| EP-2830615-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR USE IN THE TREATMENT HELMINTH INFECTION | Intervet International B.V. (NL) | 2015-02-04 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028689-A1 | N-(1-PHTHALAZIN-1-YLPIPERIDIN-4-YL)AMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080365-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT | PIGS, MTCL3, GJB2 | KMT2A 2824/4885LMNA 2161/4885PKM 2600/4885 |
| US-20150057279-A1 | HETEROARYL COMPOUNDS WITH A-CYCLIC BRIDGING UNIT | AADAC, PIGS, MTCL3 | KMT2A 2450/4885LMNA 1595/4885PKM 2998/4885 |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | KMT2A 1641/4885LMNA 1785/4885PKM 2741/4885 |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | KMT2A 1129/4885LMNA 2361/4885PKM 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.